chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Headache; chills; numbness in tips of fingers; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 49-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 25Oct2023 at 18:00 as dose 1, single (Lot number: HG2282) at the age of 49 years, in left arm for covid-19 immunisation; influenza vaccine (FLU VACCINE VII), in Oct2023 as unk unk, single (Batch/Lot number: unknown), in right arm for immunisation. The patient's relevant medical history included: "low thyroid" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing); "risk of breast cancer" (unspecified if ongoing). Concomitant medication(s) included: LEXAPRO; WELLBUTRIN; ATENOLOL; RALOXIFENE; LEVOTHYROXINE. Vaccination history included: Covid 19 vaccine (Dose 1, Single, Manufacture: Unknown), for Covid 19 immunization; Covid 19 vaccine (Dose 2, Single, Manufacture: Unknown), for Covid 19 immunization; Covid 19 vaccine (Dose 3 (Booster), Single, Manufacture: Unknown), for Covid 19 immunization; Covid 19 vaccine (Dose 4(Booster), Single, Manufacture: Unknown), for Covid 19 immunization. The following information was reported: HEADACHE (non-serious) with onset 26Oct2023 at 11:30, outcome "recovering"; CHILLS (non-serious) with onset 26Oct2023 at 11:30, outcome "recovering"; HYPOAESTHESIA (non-serious) with onset 26Oct2023 at 11:30, outcome "recovering", described as "numbness in tips of fingers". Therapeutic measures were not taken as a result of headache, chills, hypoaesthesia. Additional information: Concomitant medication was reported as other medications in two weeks. No covid prior vaccination. No covid tested post vaccination. No known allergies.
This spontaneous report as received from an unknown type reporter refers to a 15 years old patient of unknown gender. On 22-MAY-2014 the patient was vaccinated with a GARDASIL (lot#/batch# reported as J006350, expiry date: 31-MAR-2016) dose, frequency and indication unspecified. The reporter stated that GARDASIL was involved in temp changed. At the time of report, the outcome of the event was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
This spontaneous report was received from a registered nurse concerning an unknown number of patient of unknown age and gender that were vaccinated with a dose of M-M-R II (dose, dose number, lot number, expiration date and route were not reported), that was improperly stored. No adverse effect reported. Medical history and concurrent conditions were not reported. Co-suspect and concomitant therapies were not reported. This is one (1) of eight (8) reports from the same reporter. Additional information has been requested.
1720 Tdap given. 1725 nauseated - diaphoretic BP 100/70 laying down, color pale. 1745 BP 100/68 laying, nauseated. 1820 Sat up, H2O given, freezer popsicle given, BP 100/60 laying, started to get diaphoretic again. 1815 BP same, 110/60. 1830 watching TV, color pink, warm. 1850 BP 120/80. Discharged home.
Systemic: Chills-Mild, Systemic: Dizziness / Lightheadness-Mild, Additional Details: Pt complained that was light headead, chills alittle. Pt was counseled by NP and Rph. measured BP came out 117/79 we do not know the baseline. Gave patient water + candy. Asked pt if she was dizzy, if she was to walk, would she fall? No, she said was fine, can walk and drive. Counseled Pt to contact pcp tomorrow. may take tylenol if it turns into headache.
Pt given Pfizer vaccine as requested and ordered.  Discovered afterwards that there is documentation that she received a Moderna vaccine on 7/9/2021 at another facility.  Pt later denied receiving vaccine at other vaccine as documented.
pt recv vax & devel a fever as high as 105.5;pt treated w/Ibuprofen * APAP for 1wk;but fever persisted;temp rarely went below 103;MD planning to hosp pt @ date of report;22APR97 pt not hosp dx measles;
2 days later, rash began on back of neck. Day 5 rash is worse. No meds yet, but rash is spreading so starting benedryl.
Started with a headache and arm pain. Had weakness by the end of day. Went to bed, woke up with chills and shivering. The next morning, felt lightheaded, and had headache. Had muscle aches, fatigue, weakness, and moved very slowly. Did not move around too much. Took Tylenol, headache went away a little bit but still had weakness. Feels better now.
Menstrual cycle abnormal; This spontaneous case was reported by a consumer and describes the occurrence of MENSTRUAL DISORDER (Menstrual cycle abnormal) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MENSTRUAL DISORDER (Menstrual cycle abnormal). At the time of the report, MENSTRUAL DISORDER (Menstrual cycle abnormal) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.
Patient presented to pharmacy for a COVID vaccine and requested a dose of the single dose Janssen vaccine.  Per her vaccination consent form she indicated that she had not received any first doses of COVID vaccine.  After reviewing any questions or concerns she agreed to have the vaccine.  We completed all of the necessary documentation for the federal COVID vaccine program but when entering the vaccination information into the  state vaccine registry it was discovered that the patient had received a dose of pfizer vaccine at another facility on 6/26/21.  We contacted the other facility and they confirmed that the vaccine had been administered.  After confirming this with the facility we then contacted the patient.  She said that she received the first dose of a vaccine but was confused as to when she was to receive her second dose and which vaccine she needed receive.  We confirmed that she had not had any reactions to the vaccine.  We also asked if she had a primary care doctor that we could contact to inform of the incident and she disclosed that she has not seen a doctor in nearly two years.    I reviewed the side effects that the patient should be aware of from the Janssen vaccine and made sure the patient had the EUA as reference should any issues arise.  I also made sure that the patient had the  smartphone tool available on her phone so that she could report any adverse events to the CDC.  We advised the patient to not receive the second dose of the pfizer vaccine as she had completed the Janssen single dose therapy and would not need any more vaccines.  We also asked that she please contact us if she has any questions or concerns.
Was only 17 years and 9 months of age at the time vaccine was given. No known adverse reaction at time of administration.
Runny nose, sore throat, fatigue 1/22-1/24 Body aches 1/22-1/23
Presents to the hospital with cough chest pain which is exacerbated with deep inspiration. ED workup significant for hypoxia 84% on 4 L, mild hypokalemia and chest x-ray without acute findings; on admission patient was found of (+) sirs with tachypnea tachycardia; found to (+)-COVID-19 pneumonia.  Patient was admitted to the hospital; started on medications including dexamethasone, Combivent, azithromycin and received remdesivir.  During the course of admission is S upper and lower extremity DVT is ruled out.  Patient continued to improve improve and requiring less O2 supplementation as compared to on admission.  Prior to discharge patient will using 2 L of O2 (baseline).   Admitted 2/23/22-2/27/22 Pfizer 5/23/21 & 6/15/21
Alarm went off, I couldn't get up and fell back asleep (on a work-day, I always jump out of bed and get started as soon as the alarm goes off) I woke up 1/2 hour later, realized the time, forced myself to get up and call in sick to my employer. I am chilly, very weak, feel slightly nauseated and lack an appetite. I'm definitely feeling too ill to carry out my normal daily activities.
Information regarding PREVNAR 13 was received from a physician assistant regarding a patient who experienced cellulitis, tenderness on palpation, warmth, erythema and swelling. The patient received a dose on an unspecified date. On an unknown date, after the immunization, the patient experienced erythema, swelling, warmth, and tenderness on palpation at the injection site. The affected area was 14 by 11 centimeters. The child was treated in an unspecified manner for cellulitis. They suspect a problem with the product. Outcome of the events was unknown. No additional information was available at the time of this report.
Pt felt nausea with some difficulty breathing. Pt had bronchitis 1 mon previous
Day of Vaccine Friday May 14 Almost immediately following the vaccine I had a severe headache and nausea. I was unable to eat anything the entire rest of the day. A few hours later I experienced severe diarrhea.  Saturday May 15th Moderate pain at injection site Severe headache Moderate body aches Mild fatigue Moderate diarrhea  Sunday May 16th During the day Mild pain and mild swelling at the injection site Moderate headache Moderate fatigue Sharp intermittent pain in both ears that lasted a few hours After bed I had a severe headache and moderate nausea that woke me in the middle of the night.  I took tylenol and drank some gingerale.    Monday May 17th Mild headache Mild fatigue Mild nausea  Tuesday May 18th I was feeling ok with only mlid fatigue then later in the afternoon my heart started fluttering.  My pulse kept dropping into the 40's then going high into the 120's.  I was having chest pain's and my blood pressure was higher than normal.  My oxygen level was good.  Around 10pm my husband brought me to the emergency room.  My BP was 181/98 when I arrived.  They did an EKG immediately and said I had multiple PVC's.  Then they did chest x-rays, a CT scan, blood work and an echo cardiogram.  The heart monitor over the next few hours showed frequent PVC's and Bigeminy.  They started me on heparin and admitted me.    May 19th I was in the hospital and experienced a moderate headache and nausea.  They continued the heparin and IV fluids and also gave me potassium. The PVC's continued but were less frequent.  May 20th I was discharged from the hospital later in the day.  I had a moderate headache and moderate nausea.  The PVC's continued but less frequent.  May 21st Moderate headache Moderate fatigue Moderate nausea I'm not thinking clearly and I'm having troubles concentrating. My headache woke me up at 2am and I could not get back to sleep until almost 3am when the tylenol finally took the edge off.
NUMBNESS IN HAND SEVERE PAIN IN LEFT SHOULDER / ARM , GRADUALLY INCREASING TO NO RANGE OF MOTION AND  EXCRUCIATING PAIN.
In the 24 hours after getting the first dose of Pfizer I experienced shortness of breath and runny eyes and a scratchy throat
Starting 2 days after shot heart palpitations at random times of the day and that went on for two weeks. They became worse during sleeping hours so I was awake a lot of the night. Episodes of vertigo with shortness of breath when walking or rising from sleeping. Still suffering from daily headaches.
Patient was reporting immediate swelling occurred in the right breast, but was not reported to providers office until 3/29/18.
Patient after vaccine left vaccination room to go sit down about 9 minutes after she received vaccine.  Her mother went to get a cart and took patient with her and patient  went down. She hit her head on the hard cement floor. Per a person who saw what happened patients eyes were moving back and forte then rolled back and she went down. We ran out after there to see what happened . Had a technician go and call 911 and call management over. We  rolled up a jacket put under her head and some ice. Had someone with management wait with patient who was able to answer questions like where she was, year, date and where she was. She answered all questions just had pain. Once the EMS arrived they did take her to the hospital.
Patient reports she has a rash that is itchy on her left deltoid where she got her last COVID-19 injection (Thursday 8/18/2022). RN asked her if she called her PCP yet. She will call her PCP next and report it to them. She took some Benadryl before calling.
Rash; Started to get tired/ severe exhaustion; Redness/ Small red patch/getting bigger now; Dried cough; Soreness; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of COUGH (Dried cough), PAIN (Soreness), ERYTHEMA (Redness/ Small red patch/getting bigger now), RASH (Rash) and FATIGUE (Started to get tired/ severe exhaustion) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), DULOXETINE HYDROCHLORIDE (CYMBALTA), LOSARTAN, APIXABAN (ELIQUIS) and VITAMINS NOS for an unknown indication.   On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PAIN (Soreness). On 06-Feb-2021, the patient experienced COUGH (Dried cough). On 08-Feb-2021, the patient experienced ERYTHEMA (Redness/ Small red patch/getting bigger now). On 09-Feb-2021, the patient experienced FATIGUE (Started to get tired/ severe exhaustion). On an unknown date, the patient experienced RASH (Rash). At the time of the report, COUGH (Dried cough), PAIN (Soreness), ERYTHEMA (Redness/ Small red patch/getting bigger now) and FATIGUE (Started to get tired/ severe exhaustion) had not resolved and RASH (Rash) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-008779 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 23-Apr-2021: New event added
came to ED with chest pain; known COVID for approx. 1 week chest pain x1 day which radiaated to shoulder EKG done in cardiology office with concern for STEMI - sent to ED for cardiac cath. day after procedure still feels SOB but no fever, chills , n/v/d
low grade fever noc of 22FEB96 inc next day;t103.7 to 105.1 x 5-6days;mom called ER told to give 1/2 APAP & Motrin;went to MD 22 & 24FEB one ear sl red,sl red throat;placed on amoxil then keflex,face swelled 27FEB p/crying all day;rash
Hep A dose 1 in May2015, dose 2 not received; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 72-year-old male patient who received Hepatitis A vaccine for prophylaxis.   Previously administered products included Hepatitis A vaccine (1st dose received on 20th May 2015 from lot number 2F559).   On an unknown date, the patient did not receive the 2nd dose of Hepatitis A vaccine. On an unknown date, unknown after receiving Hepatitis A vaccine, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 02-NOV-2022 Reporter's Comment: The reporter reported that the patient did not receive the 2nd dose within the recommended timeframe. The reporter wanted to know if the patient need to start over the series. The reporter stated that the patient had a lot number 2F559 and he stated that it was a GlaxoSmithKline vaccine, but not the actual brand name of the vaccine. The lot number did not match with a GlaxoSmithKline vaccine.  The vaccine was administered at a different facility. The reporter did not consent to follow up. Additional supportive information: Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination.
Patient received 0.5mL of moderna (original monovalent) vaccine, instead of bivalent moderna dose. Patient has been informed.
Information has been received from a nurse concerning a 79 year old white female with hypothyroidism, drug hypersensitivities to codeine, neomycin sulfate, polymyxin B sulfate and bacitracin zinc (Neosporin), and fluticasone nasal (Flonase) and no other medical history, who on 30-Aug-2007 at 10:00 was vaccinated with the first SC dose of Zostavax (lot #658081/0743U) in the left arm.  On approximately 03-Sep-2007 the patient developed localized erythema > 50 cm in size.  No medical attention was sought.  On 07-Sep-2007 the patient recovered.  Additional information has been requested.
Tinnitus in left ear started less than 2 hours after vaccine and hasn?t let up since
The pt subsequently developed a fever of 104 and a rash all over his body. The pt sought unspecified medical attention. No further information is available.
10 minutes after shot got dizzy, syncopized. now asymptomatic. no allergic symptoms.
Vaccine administered to pregnant patient; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Vaccine administered to pregnant patient) in a 40-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Apr-2021 at 8:45 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 07-Jan-2021 and the estimated date of delivery was 12-Oct-2021. On 02-Apr-2021, the patient experienced EXPOSURE DURING PREGNANCY (Vaccine administered to pregnant patient). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twelfth week of the pregnancy.  On 02-Apr-2021, EXPOSURE DURING PREGNANCY (Vaccine administered to pregnant patient) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessment.  No medical problems or concomitant medications provided. Treatment information was not provided.
Received shot on 5/8/21 at 11:00am. States nauseated, dizzy and light-headed at 5:00pm on 5/8/21. Also c/o headache. Headache will go away with tylenol. States nausea, dizzy, and light-headedness symptoms have been continuous since receiving second dose.
Janssen COVID-19 Vaccine EUA- Had a 101 degree fever (with headache, body ache, and shaking) the day after vaccination, and a 99 degree fever (I'm usually about 96.5 degrees) the next two days. Left arm has gotten progressively sorer over three days and is currently (3 days in) swollen and feverish feeling in an area the size of a baseball around the injection site.
190 patients (9 different lot numbers) received a vaccine past the beyond used by date; 190 patients (9 different lot numbers) received a vaccine past the beyond used by date; no adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date), PRODUCT STORAGE ERROR (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (no adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date), PRODUCT STORAGE ERROR (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date), PRODUCT STORAGE ERROR (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and PRODUCT STORAGE ERROR (190 patients (9 different lot numbers) received a vaccine past the beyond used by date).    Concomitant products were not provided. Unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. Treatment medication were not reported.    This case was linked to US-MODERNATX, INC.-MOD-2023-704335 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704335:Master case
experienced neurologic reaction; patient can not drive; he needs a walker to walk; he needs a walker to walk; This non-serious case was reported by a physician via call center representative and described the occurrence of neurologic reaction in a male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On 06-OCT-2023, the patient received Arexvy. In OCT-2023, an unknown time after receiving Arexvy, the patient experienced neurologic reaction (Verbatim: experienced neurologic reaction), activities of daily living impaired (Verbatim: patient can not drive), walking difficulty (Verbatim: he needs a walker to walk) and walker user (Verbatim: he needs a walker to walk). The outcome of the neurologic reaction, activities of daily living impaired, walking difficulty and walker user were not resolved.   It was unknown if the reporter considered the neurologic reaction, activities of daily living impaired, walking difficulty and walker user to be related to Arexvy.     It was unknown if the company considered the neurologic reaction, activities of daily living impaired, walking difficulty and walker user to be related to Arexvy.   Additional Information: GSK Receipt Date: 24-OCT-2023 The caller was the GlaxoSmithKline representative called to report an AE (adverse event) and she stated HCP (health care professional) reported that a patient received Arexvy and experienced neurologic reaction shortly thereafter.  The patient could not drive and he needed a walker to walk.  No other information provided. The reporter consented to follow up.